SCHEMBL24137526

SCHEMBL24137526

Nc1n[nH]c2cc(-c3cnc(NCc4ccc(OC5CC5)cc4)nc3)ccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 1/20 0.45
▸ PDPK1 O15530 10/20 0.43
▸ SGK1 O00141 3/20 0.43
▸ JAK2 O60674 1/20 0.42
▸ FGFR1 P11362 1/20 0.41
▸ CLK2 P49760 1/20 0.40
▸ CLK3 P49761 1/20 0.40
▸ DYRK1A Q13627 1/20 0.40
▸ MAP2K4 P45985 1/20 0.39
▸ AURKA O14965 3/20 0.39
▸ TGFBR1 P36897 3/20 0.39
▸ AURKB Q96GD4 3/20 0.39
▸ ROCK1 Q13464 2/20 0.39
▸ SCN5A Q14524 1/20 0.39
▸ SCN9A Q15858 1/20 0.39
▸ CHUK O15111 1/20 0.38
▸ RPS6KB1 P23443 1/20 0.38
▸ CDK2 P24941 1/20 0.38
▸ KDR P35968 1/20 0.38
▸ SYK P43405 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24137528 0.96 BTK (0.51) BTKPDPK1SGK1JAK2FGFR1
SCHEMBL25933254 0.95 BTK (0.50) BTKPDPK1SGK1JAK2FGFR1
SCHEMBL24137497 0.86 MAP2K4 (0.54) PDPK1JAK2FGFR1MAP2K4AURKA
SCHEMBL25933252 0.84 JAK2 (0.52) BTKPDPK1SGK1JAK2FGFR1
SCHEMBL24137793 0.83 MAPK1 (0.48) PDPK1JAK2FGFR1MAP2K4SCN5A
SCHEMBL25933239 0.82 ABL1 (0.54) PDPK1SGK1JAK2AURKATGFBR1
SCHEMBL24137503 0.82 MAP2K4 (0.55) PDPK1SGK1JAK2MAP2K4AURKA
SCHEMBL24137502 0.82 JAK2 (0.48) PDPK1SGK1JAK2AURKATGFBR1
SCHEMBL24137787 0.82 JAK2 (0.61) PDPK1SGK1JAK2FGFR1AURKA
SCHEMBL24137524 0.79 SGK1 (0.48) PDPK1SGK1JAK2DYRK1AAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234935-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2023-07-27 — — US disclosed
US-20230234935-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2023-07-27 — — US disclosed
WO-2021263129-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2021-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234935-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE PACSIN2, MAP3K20, PHKG1 BTK 417/4885PDPK1 123/4885SGK1 191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback